Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $328.5752W HIGH $603.88
Volume
2.53 M
Value Traded
1.25 B
Short % Float
2.31%
+5.99%Week
+17.6%1 Month
+2.12%3 Month
-7.81%6 Month
+56.46%5 Year
+21,805.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
146.76 B
EPS (TTM)
8.88
P/E Ratio
46.76
Ent. Value
138.13 B
Total Shares
353.28 M
Float Shares
350.81 M
Insiders
0.70%
Institutions
89.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ISRG Catalyst Timeline
Dated clinical, regulatory and corporate events for Intuitive Surgical, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Intuitive Surgical, Inc.
273Total events
1Upcoming
59Tier-1 (high impact)
2008 to 2027Coverage
Event history 50
▲Product LaunchPost-Market
da Vinci 5 software updates (telepresence, mobile login, SimNow 2) available in US starting June 2026
▲Product LaunchPost-Market
Force Feedback instruments use increased from 6 to 15 uses (one instrument 10 uses) - already effective
◆AcquisitionCorporate
Intuitive completes acquisition of da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica
▲FDA ApprovalFDA Decision
FDA clearance of da Vinci 5 for certain cardiac procedures
cardiac procedures (mitral valve repair, IMA mobilization for cardiac revascularization)source ↗
▲Label ExpansionFDA Decision
FDA clearance expands da Vinci SP indications to include inguinal hernia repair, cholecystectomy, and appendectomy
inguinal hernia repair, cholecystectomy, appendectomysource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA cleared software advancements for Ion endoluminal system
lung cancersource ↗
▲FDA Feedback ReceivedFDA Meeting
FDA 510(k) clearance for Force Gauge, In-Console Video Replay, and Network CCM software features
▲Product LaunchPost-Market
Announcement of Force Gauge, In-Console Video Replay, and Network CCM features for da Vinci 5
▲EU ApprovalEx-US Regulatory
da Vinci 5 receives CE mark approval for adult and pediatric use in Europe
minimally invasive endoscopic procedures across abdominopelvic and thoracoscopic surgical procedures, including urologic, gynecologic, and general laparoscopic proceduressource ↗
▲Other Regulator MilestoneEx-US Regulatory
da Vinci 5 receives EU MDR certification in Europe
minimally invasive endoscopic procedures (adult and pediatric, abdominopelvic and thoracoscopic, excluding force feedback)source ↗
▲Other Regulator MilestoneEx-US Regulatory
da Vinci 5 receives regulatory clearance in Japan
all surgical specialties and procedures indicated for da Vinci Xi except cardiacsource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA clearance of da Vinci SP for transanal local excision/resection
transanal local excision/resectionsource ↗
●Quarterly UpdateCorporate
Intuitive provides 2025 financial outlook: da Vinci procedure growth ~17-17.5%, non-GAAP gross margin 67-67.5%, non-GAAP opex growth 11-13%
●Timing GuidancePresentation
Intuitive provides 2025 full-year guidance: procedure growth ~15.5%-17%, non-GAAP gross margin 66%-67%, operating expense growth 10%-14%
▲Other Regulator MilestoneEx-US Regulatory
South Korea regulatory clearance for da Vinci 5
urologic, general, gynecologic, thoracoscopic, thoracoscopically-assisted cardiotomy, transoral otolaryngology surgical proceduressource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA cleared labeling revision for da Vinci X and Xi specific to radical prostatectomy
radical prostatectomysource ↗
▲FDA Filing AcceptedRegulatory Filing
FDA cleared labeling revision for da Vinci X and Xi specific to radical prostatectomy
radical prostatectomysource ↗
▲FDA Filing AcceptedRegulatory Filing
Intuitive Surgical Receives Additional FDA 510(k) Clearance for Ion Endoluminal System (Ion Fully Articulating Catheter)
◆Oral PresentationPresentation
Teleconference to discuss da Vinci 5 features and launch plans
▲NMPA NDA ApprovalIonApprovedEx-US Regulatory
NMPA regulatory clearance for Ion endoluminal system in China
endoluminalsource ↗
▲FDA Feedback ReceivedFDA Meeting
FDA clearance for da Vinci 5 system
all surgical specialties and procedures indicated for da Vinci Xi except cardiac, pediatric, and force feedback in hysterectomy/myomectomysource ↗
▲NMPA NDA ApprovalEx-US Regulatory
NMPA regulatory clearance for Ion endoluminal system in China
▲FDA Filing AcceptedRegulatory Filing
Intuitive Surgical Received Additional 510(K) Clearance For Ion Endoluminal System
▲Other Regulator MilestoneEx-US Regulatory
CE mark certification obtained for da Vinci SP system in Europe
endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, transanal colorectal, and breast surgical proceduressource ↗
▲Product LaunchPost-Market
Planned commercialization of da Vinci SP system in select major European countries
Past FDA Catalysts and PDUFA Decisions
How ISRG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C46 / 100
Pipeline Score
$1.2B
Pipeline Value
Not rated
Valuation Signal
4
Drugs Scored
0.0x
rNPV / MCap
Top 26%
Large Pharma(rank 172 of 658)
Percentile Rank
Intuitive Surgical, Inc. carries a moderate pipeline score (46/100), with $1.2B risk-adjusted pipeline value, led by Administration of IS-002 in Prostate Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Administration of IS-002 Small moleculeCompletedNCT05946603 | Prostate Cancer | Phase 2 | COMPLETED | 59 | May 23, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ISRG program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Widman FredrikOfficer (VP Corporate Controller) | Option | 546 1,572 held | $79.64 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ISRG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1.2 % (-36.8 %) | 62.79 M | 157.90 K | -24.34% ( -50.80 K) |
ISRG Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-13 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ISRG ranks across every disease it competes in
Competitive Position is a premium feature
See how ISRG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialISRG News
ISRGIntuitive announces expanded indication for da Vinci SP in Europe
Intuitive has received CE mark approval for the da Vinci SP surgical system, allowing its use in transvaginal gynecologic procedures. This marks a significant expansion of the system's applications in Europe, which already includes various surgical procedures. The approval aims to enhance access to minimally invasive options for women, potentially improving recovery experiences and outcomes.
Read more →ISRG▼ -14.1%on this news
Intuitive Announces Second Quarter Earnings
Intuitive Surgical reported strong financial results for Q2 2026, with a revenue increase of 19% to $2.89 billion, driven by a rise in procedure volumes and system placements. The company placed 468 da Vinci surgical systems, marking a significant growth from the previous year. Additionally, net income attributable to Intuitive increased to $818 million, reflecting a positive outlook for the company's performance.
Read more →ISRGIntuitive Announces New Chief Commercial and Marketing Officer Taylor Patton Current Chief Commercial and Marketing Officer Henry Charlton to become SVP of Global Business Operations
Intuitive has appointed Taylor Patton as the new Chief Commercial and Marketing Officer, effective July 1. Patton, who has nearly two decades of experience with the company, will join the Executive Leadership team and succeed Henry Charlton, who will transition to Senior Vice President of Global Business Operations. The leadership change aims to enhance Intuitive's global impact and ensure effective support for customers in the minimally invasive care sector. Both leaders emphasized their commitment to improving patient outcomes and expanding Intuitive's technology across healthcare systems worldwide.
Read more →ISRGIntuitive Announces Innovations to Advance Quintuple Aim
Intuitive (NASDAQ: ISRG) recently announced a series of innovations aimed at enhancing its da Vinci robotic surgical system and its supporting ecosystem. Key updates include telepresence enhancements allowing remote guidance during surgeries, improved mobile login for surgeons, and the introduction of new simulation exercises for better surgeon training. The company is also focusing on increasing the reliability and security of its products, addressing demand with expanded use capabilities for Force Feedback instruments. These advancements are set to be available in the U.S. starting in June 2026, pending regulatory clearance, highlighting Intuitive’s commitment to improving patient care and outcomes.
Read more →ISRGIntuitive Announces First Quarter Earnings
Intuitive Surgical reported strong financial results for Q1 2026, with a 23% increase in revenue to $2.77 billion. The company saw a 17% growth in worldwide procedures, driven by a 16% increase in da Vinci procedures and a remarkable 39% growth in Ion procedures. Additionally, net income rose to $822 million, reflecting robust operational performance and increased system placements.
Read more →ISRGINTUITIVE ANNOUNCES FIRST QUARTER EARNINGS
Intuitive Surgical has reported strong financial results for the first quarter of 2026, indicating robust growth in both revenue and surgical procedures. The company's revenue reached $2.77 billion, marking a 23% increase compared to the same quarter last year, driven by a higher volume of da Vinci and Ion procedures. Additionally, the number of surgical systems placed rose significantly, underscoring the ongoing adoption of its robotic-assisted technologies. However, the company also faced a decrease in cash reserves and potential challenges due to tariffs affecting future margins.
Read more →ISRGIntuitive Expands Investment and Footprint in Europe
Intuitive (NASDAQ:ISRG) has completed its acquisition of the da Vinci and Ion distribution business from ab medica and its affiliates, marking a significant expansion of its direct operations in Europe. This move aims to enhance support for customers and increase access to minimally invasive care across several countries. The integration of approximately 250 employees is expected to drive innovation and improve patient outcomes.
Read more →ISRGDa Vinci 5 Cleared for Cardiac Procedures
Intuitive's da Vinci 5 system has received FDA 510(k) clearance for specific cardiac procedures, including mitral valve repair. This advancement aims to enhance minimally invasive cardiac surgery, reducing the need for sternotomy and associated complications. The company plans to establish dedicated training programs and infrastructure to support the adoption of this technology in cardiac care.
Read more →ISRG20 Million Patients Benefit from da Vinci Surgery Globally
Intuitive Surgical has announced that over 20 million patients globally have undergone procedures using its da Vinci surgical systems, marking a significant milestone. In 2025 alone, more than 3.1 million procedures were performed. The company emphasizes its commitment to innovation and improving patient outcomes through advanced technology and training.
Read more →ISRGIntuitive Announces Fourth Quarter Earnings
Intuitive Surgical reported strong financial results for Q4 2025, with revenues reaching $2.87 billion, a 19% increase from the previous year. The growth was driven by higher procedure volumes and increased placements of da Vinci systems. The company also highlighted a robust financial outlook for 2026, despite potential risks from tariffs and legal uncertainties.
Read more →ISRGINTUITIVE ANNOUNCES FOURTH QUARTER EARNINGS
Intuitive Surgical, Inc. reported strong financial results for the fourth quarter of 2025, with a 19% increase in revenue compared to the previous year, totaling $2.87 billion. Significant growth was seen in both da Vinci and Ion procedures, with respective increases of 17% and 44%. The company's installed base of da Vinci surgical systems also grew by 12%. However, for 2026, the company projects a slowdown in procedure growth to approximately 13-15% and an increase in operational expenses between 11% and 15%, raising concerns about future margins and profitability.
Read more →ISRGIntuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results
Intuitive Surgical (ISRG) reported preliminary financial results for Q4 and full year 2025, showing significant revenue growth. Q4 revenue reached approximately $2.87 billion, up 19% year-over-year, driven by increased procedure volume and system placements. The company anticipates continued growth in 2026, with a projected increase in worldwide da Vinci procedures.
Read more →ISRGInvestor Relations (408) 523-2161 INTUITIVE ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025
Intuitive Surgical (ISRG) has released its preliminary fourth quarter and full year 2025 financial results, showcasing significant growth. The company reported an 18% increase in procedures compared to Q4 2024, with revenue for the quarter at approximately $2.87 billion, a 19% rise year-over-year. Full year revenue reached approximately $10.06 billion, marking a 21% increase from 2024. The improvements were largely driven by increased adoption and utilization of the da Vinci surgical systems and the Ion endoluminal system. However, these results are preliminary and subject to final audit adjustments.
Read more →ISRGIntuitive Announces Expanded Indications for da Vinci SP
Intuitive has received FDA clearance for its da Vinci Single Port (SP) surgical system to perform inguinal hernia repair, cholecystectomy, and appendectomy. This expansion builds on existing clearances in various surgical areas, enhancing the system's capabilities for minimally invasive procedures. The da Vinci SP allows for advanced surgical precision through a single incision, promoting better patient outcomes.
Read more →ISRG▲ +13.9%on this news
Intuitive Announces Third Quarter Earnings
Intuitive Surgical (ISRG) reported strong financial results for Q3 2025, with revenues reaching $2.51 billion, a 23% increase from the previous year. The growth was driven by higher procedure volumes and an increase in da Vinci system placements. GAAP net income also rose significantly to $704 million, although the company noted a decrease in cash reserves due to stock repurchases. Looking ahead, Intuitive anticipates challenges from tariffs affecting its financial outlook.
Read more →ISRGINTUITIVE ANNOUNCES THIRD QUARTER EARNINGS
Intuitive Surgical (ISRG) reported robust third quarter results for 2025, with total revenue climbing to $2.51 billion, a 23% increase from the previous year. Worldwide procedures using da Vinci and Ion systems grew by about 20%, driven by a significant rise in both device placements and overall adoption. The company also posted a notable increase in net income, reflecting strong market demand. However, Intuitive expects challenges ahead, including potential impacts from tariffs affecting profit margins in 2025.
Read more →ISRGIntuitive expands AI and advanced imaging integration in Ion Endoluminal System
Intuitive (NASDAQ:ISRG) has received FDA clearance for software advancements in its Ion endoluminal system, enhancing AI integration and imaging capabilities. These improvements aim to assist physicians in accurately diagnosing lung cancer by enabling better navigation and biopsy procedures. A limited launch is set for 2026, reflecting Intuitive's commitment to innovation in lung cancer care.
Read more →ISRGIntuitive Introduces Real-Time Surgical Insights for da Vinci 5
Intuitive has launched new software capabilities for its da Vinci 5 surgical system, aimed at improving surgical efficiency and patient outcomes. Key features include Force Gauge, which provides real-time feedback on force applied during surgery, and In-Console Video Replay for reviewing procedures without losing focus. These updates, cleared by the FDA, reflect Intuitive's commitment to innovation in robotic-assisted surgery.
Read more →About Intuitive Surgical, Inc.
Headquarters1020 KIFER ROAD, SUNNYVALE, CA, 94086
BIOPHARMAWATCH ELITE PLUS
Trade the next ISRG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime